Document:

Exhibit
10.2

 

CONSULTING
AGREEMENT

 

THIS
CONSULTING AGREEMENT (this “Agreement”), dated as of December 1, 2022 is hereby entered into by and between OncoCyte
Corporation (the “Company”) and Ronald A. Andrews (the “Consultant” and, collectively with the
Company, the “Parties”).

 

In
consideration of the mutual covenants and promises contained herein, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged by the Parties, the Parties agree as follows:

 

1.
 Engagement. The Consultant is being engaged by the Company as an independent contractor
commencing on December 2, 2022 (the “Commencement Date”) and continuing until February 28, 2023, unless terminated
earlier pursuant to Section 11 below (the “Consulting Term”). The term of this Agreement may be extended by the mutual
written and duly executed agreement of the Parties.

 

2.
 Services. The services hereunder are set forth in Appendix A hereto (collectively,
the “Consulting Services”). During the Consulting Term, the Consultant shall perform the Consulting Services remotely
from Consultant’s office in Tennessee, unless otherwise requested by the Chairman of the Board of Directors (the “Board”)
or his or her designee. The Company liaison who shall be the point of contact for the Consultant while the Consultant performs the Consulting
Services will be the Chairman of the Board or his or her designee.

 

3.
 Independent Contractor.

 

(a) The
Parties agree that the Consultant will be an independent contractor of the Company. The Consultant shall perform the Consulting Services
utilizing Consultant’s own tools, equipment, means and manner. Nothing in this Agreement is intended to, or shall be deemed to,
create any partnership, agency, or joint venture relationship between or among the Consultant or any of Consultant’s employees,
agents, or subcontractors (collectively, with the Consultant, the “Consultant Parties”), on the one hand, and the
Company or any of the Company Parties (as defined below), on the other hand.

 

(b) Neither
the Consultant nor any of the other Consultant Parties is eligible for or will receive any of the rights, privileges, interests, benefits,
or perquisites that the Company extends to its employees, including, but not limited to, any wages, compensation, commissions, bonuses,
profit sharing benefits, carried interest, equity, phantom equity, performance compensation, pension benefits, savings benefits, 401(k)
benefits, vacation, sick pay, or severance benefits, even if Consultant or any Consultant Party is deemed an employee of the Company
by any agency, arbitrator, or tribunal. The Consultant and the Consultant Parties will not participate in any of the plans or programs
that the Company makes available to its employees and hereby reject and release any and all right, claim, or interest to any and all
payments, compensation, rights, privileges, benefits, and/or perquisites from any of the Company Parties.

 

4.
 Consulting Fee and Related Matters.

 

(a) Consulting
Fee: The Company will compensate the Consultant by granting the Consultant options to purchase 50,000 shares of Company common stock
pursuant to the Company’s 2018 Equity Incentive Plan, as amended from time to time (the “Plan” and such options,
the “Consulting Options”). The Consulting Options shall be granted on the third (3rd) business day following the Commencement
Date and shall vest as to one-third of the Consulting Options on each December 31, 2022, January 31, 2023 and February 28, 2023, subject
to the Consultants continued compliance with any restrictive covenants by which the Consultant may be bound and continuous provision
of Consulting Services under this Agreement on each applicable vesting date, except as otherwise provided in Section 11, and shall be
subject to such other terms and conditions as determined by the Board. The exercise price of the Consulting Options shall be the fair
market value of a share of Company Common Stock (as defined in the Plan) on the applicable effective date of grant, determined in accordance
with the Plan.

 

    	1

     

    

 

(b) Consulting
Expenses. During the Consulting Term, the Company shall reimburse the Consultant for ordinary and necessary out-of-pocket and documented
business expenses incurred by the Consultant in the performance of duties for the Company in accordance with the Company’s usual
policies in effect from time to time and upon the receipt by the Company of satisfactory written substantiation of such expenses; provided,
however, that any expense exceeding $100 shall require pre-approval by the Chairman of the Board or his or her designee.

 

(c) Consultant
Party Compensation/Taxes/Benefits. The Consultant shall bear sole responsibility for any and all wages and other compensation due
to Consultant and/or any Consultant Party. The Consultant shall also bear sole responsibility for all federal, state, and local income
tax withholding, social security taxes, workers’ compensation coverage, unemployment insurance, liability insurance, health and/or
disability insurance, retirement benefits, health and welfare benefits, pension benefits, other payments or expenses due or owed to,
for, or with respect to any Consultant Party. Consultant and the Consultant Parties shall, jointly and severally, indemnify and hold
harmless the Company and each of the Company Parties from and against any and all taxes or other liability (including interest, penalties,
accountants’ and attorneys’ fees, costs, and expenses) which may be assessed, imposed, or incurred as a result of or relating
to this Agreement or any amounts received by Consultant or the Consultant Parties from the Company or the Company Parties. In the event
the Company or any of the Company Parties is required to make any payments (i) that are Consultant’s obligations under this Agreement,
or (ii) to the Internal Revenue Service or any other taxing authority in respect of any taxes (other than withholding), Consultant shall,
upon receipt of written notice from the Company, remit to the Company an amount equal to such payments, within ten (10) business days
from such notice.

 

(d) Insurance.
The Consultant shall carry appropriate insurance in connection with the Consulting Services, naming the Company and its affiliates
and their respective officers, directors, and employees as additional insureds, and shall, upon request, furnish the Company with a
certificate of insurance verifying such coverage.

 

5.
 Company Protections.

 

(a) During
the Consultant’s engagement as an independent contractor performing the Consulting Services for the Company, the Consultant Parties
may have access to or otherwise become familiar with certain Confidential Information (as defined below) that is proprietary to the Company
Parties and/or provides the Company Parties with a crucial competitive advantage. Consultant agrees that the Consultant and the Consultant
Parties will not divulge, use, publish, or in any other manner reveal any Confidential Information except (x) during Consultant’s
engagement with the Company as required for, and to the extent authorized by the Company, in furtherance of the proper performance of
the Consulting Services, or (y) as discussed with, and approved in writing by the Company. For purposes of this Agreement, “Confidential
Information” includes any and all non-public information, confidential information, proprietary information, trade secrets,
or other information (whether oral or written, whether maintained in hard copy, electronically, or otherwise) regarding the business
or affairs of the Company Parties, including, without limitation, (i) trade secrets, inventions, algorithms, mask works, ideas, processes,
formulas, software in source or object code, data, programs, other works of authorship, know-how, improvements, discoveries, developments,
designs and techniques and any other proprietary technology and all intellectual property rights, and genetic and protein biomarkers
of any and all kinds used in or related to Company diagnostic tests, products, or research, even if not patented or patentable; (ii)
information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements,
licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining
business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing
and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business,
suppliers and supplier information, and purchasing; (iii) information regarding customers and potential customers of Company, including
customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company,
proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided
to customers and potential customers of Company and other non-public information relating to customers and potential customers; (iv)
information regarding any of Company’s business partners and their services, including names, representatives, proposals, bids,
contracts and their contents and parties, the type and quantity of products and services received by Company, and other non-public information
relating to business partners; (v) information regarding personnel, employee lists, compensation, and employee skills; and (vi) any other
non-public information which a competitor of Company could use to the competitive disadvantage of Company. For purposes of this Agreement,
(i) the “Company Entities” means Company and each and all of Company’s respective affiliates and subsidiaries,
and including each and all of their respective advisory, management, and partner entities and/or funds and any successor or permitted
transferee of any of the foregoing; and (ii) the “Company Parties” means, collectively, each and all of the Company
Entities and each and all of their respective current and former shareholders, interest holders, unit holders, advisors, managers, officers,
directors, partners, principals, members, employees, fiduciaries, representatives, and agents.

 

    	2

     

    

 

(b) Upon
ceasing to perform the Consulting Services for the Company, or at any other time requested by the Company, the Consultant Parties shall
return all Company Confidential Information, documents, or other Company property.

 

(c) Except
as provided in Section 5(d), below, the Consultant Parties agree that in the event they are served with a subpoena, document request,
information request, interrogatory, or any other legal process (i) that will or may require any Consultant Party to disclose any Confidential
Information, or (ii) relating to the Company Parties, the Consultant will immediately notify the Chairman of the Board of such fact,
in writing, and provide a copy of such subpoena, document request, interrogatory, or other legal process. The Consultant Parties further
agree to cooperate with the Company in any lawful response to such subpoena, document request, information request, interrogatory, or
legal process.

 

(d) In
accordance with the Defend Trade Secrets Act, 18 U.S.C. § 1833(b), and other applicable law, nothing in this Agreement, any other
agreement, or any Company policy shall prevent the Consultant Parties from, or expose the Consultant Parties to criminal or civil liability
under foreign, or U.S. federal or state trade secrets law for, (i) directly or indirectly sharing any trade secrets, Confidential Information,
or other information (except information protected by the Company’s attorney-client or work product privilege) with an attorney,
law enforcement, or with any foreign, federal, state, or local governmental agency, official, or entity (including the Department of
Justice, the Securities and Exchange Commission, the Equal Employment Opportunity Commission, any analogous state or local agencies,
the Congress, and any agency Inspector General), for the purpose of reporting, investigating, complaining about, or cooperating with
respect to a suspected violation of law (including any whistleblower retaliation claim), whether in response to a subpoena or otherwise,
without notice to the Company, or (ii) disclosing trade secrets in a complaint or other document filed in an arbitration, lawsuit, or
other proceeding (including any whistleblower retaliation claim), provided that the filing is made under seal.

 

(e) Consultant
acknowledges and agrees that Consultant is bound by certain restrictive covenants pursuant to the Confidential Separation Agreement and
General Release of All Claims by and between Consultant and the Company, dated December 1, 2022, and that nothing contained herein shall
be deemed to abrogate such obligations.

 

    	3

     

    

 

6.
 Compliance with Law. In rendering the Consulting Services, the Consultant Parties will
comply with all applicable laws, rules, and regulations, including but not limited to any applicable standards governing the collection,
use, storage, and disclosure of information. The Consultant Parties represent that they will maintain appropriate controls and procedures
to ensure the Consultant Parties’ compliance with the foregoing. The Consultant Parties assume full responsibility for complying
with (x) any registration, licensing or other relevant laws affecting the Consulting Services to be provided by the Consultant Parties,
and possesses all the required licenses, registrations and authorizations in each relevant jurisdiction and with respect to the Consulting
Services, and (y) any applicable immigration laws or other laws regarding any lawful authorization required to perform the Consulting
Services, and possess all required authorizations in each relevant jurisdiction with respect to the same.

 

7.
 No Authority. The Consultant acknowledges and agrees that the Consultant Parties do
not have authority to act on behalf of, or otherwise bind, any of the Company Parties. Accordingly, the Consultant Parties may not enter
into any agreements on behalf of or purport to bind any Company Party, or represent to any person or entity that any Consultant Party
has the power to create any obligation, express or implied, on behalf of any Company Party without the Company’s express prior
written consent. The Consultant Parties also acknowledge and agree that the Consultant Parties do not have investment discretion or any
authority to enter into agreements with respect to any accounts or assets, nor do they exercise any voting or other rights or privileges
associated with the ownership of such accounts or assets.

 

8.
 Intellectual Property. The Consultant Parties agree that the Company is the exclusive
owner of all discoveries, developments, intellectual property, inventions (whether or not patentable), methods, processes, trade secrets,
trademarks, domain names, computer programs and code (including source code and object code), research, original works of authorship,
writings, or other work product invented, conceived, developed, authored, reduced to practice, or otherwise made (collectively, “Created”)
by the Consultant Parties, whether individually or jointly with others, whether in whole or in part in connection with the Consultant
Parties’ performance of the Consulting Services or on the Company’s time or with the use of the Company Parties’ information,
resources, or materials (collectively, “Developments”), and the Consultant Parties hereby assign any and all right,
title, and interest in and to such Developments, including the intellectual property rights therein, to the Company, effective automatically
as and when each such Development is Created. For the avoidance of doubt, any copyrightable subject matter embodied in any Development
will be considered a “work made for hire” within the meaning of the copyright laws of the United States of America (17 U.S.C.
§ 101 et seq.) with initial ownership of such subject matter vesting in the Company. To the extent any Development is not deemed
a “work made for hire,” or to the extent that the Company would not otherwise automatically own any and all Developments,
including all intellectual property rights therein, the Consultant Parties hereby assign all right, title, and interest in and to such
Developments, including the intellectual property rights therein, to the Company, effective automatically as and when each such Development
is Created. The Company shall have the full worldwide right to use, assign, license and/or transfer all rights in, with, to, or relating
to any and all Developments (and all intellectual property rights therein). Whenever requested to do so by the Company (whether during
the Consulting Term or thereafter), the Consultant Parties will execute any instruments, and do all other things that the Company deems
necessary or appropriate to evidence, confirm, or give effect to the foregoing assignment or to apply for and obtain patents or trademark
or copyright registrations, or to otherwise protect the Company’s interest therein (without additional compensation to the Consultant).

 

    	4

     

    

 

9.
 Arbitration. It is the intention of Consultant and Company that the Federal Arbitration
Act and the California Arbitration Act shall apply with respect to the arbitration of disputes, claims, and controversies pursuant to,
arising under, or in connection with this Agreement. Except for injunctive proceedings against unauthorized disclosure of confidential
information or other actual or threatened breach of this Agreement that may cause irreparable and continuing injury to the Company or
its subsidiaries or affiliates for which there is no adequate remedy at law (and upon the issuance or denial of an injunction the underlying
merits of any dispute will be resolved in accordance with the remainder of this Section), any and all claims or controversies between
Company or any Subsidiary and Consultant, including but not limited to (a) those involving the construction or application of any of
the terms, provisions, or conditions of this Agreement or the Policies; (b) all contract or tort claims of any kind; and (c) any claim
based on any federal, state, or local law, statute, regulation, or ordinance, shall be settled by arbitration in accordance with the
then current Commercial Dispute Resolution Rules of the American Arbitration Association (“AAA”) or the Commercial Arbitration
Rules & Procedures of the Judicial Arbitration and Mediation Service (“JAMS”), as selected by Company or a Subsidiary.
Judgment on the award rendered by the arbitrator(s) may be entered by any court having jurisdiction over Company and Consultant. The
location of the arbitration shall be San Francisco, California. Unless Company or a Subsidiary and Consultant mutually agree otherwise,
the arbitrator shall be a retired judge selected from a panel provided by the AAA or JAMS. Company, or a Subsidiary, if the Subsidiary
is a party to the arbitration proceeding, shall pay the arbitrator’s fees and costs. Consultant shall pay for Consultant’s
own costs and attorneys’ fees, if any. Company and any Subsidiary that is a party to an arbitration proceeding shall pay for its
own costs and attorneys’ fees, if any. However, if any party prevails on a statutory claim which affords the prevailing party attorneys’
fees, the arbitrator may award reasonable attorneys’ fees and costs to the prevailing party. CONSULTANT UNDERSTANDS AND AGREES
THAT THIS AGREEMENT TO ARBITRATE CONSTITUTES A WAIVER OF CONSULTANT’S RIGHT TO A TRIAL BY JURY OF ANY MATTERS COVERED BY THIS AGREEMENT
TO ARBITRATE. Nothing in this Section shall be construed in a manner that would violate any law.

 

10. Warranties

 

(a) The
Consultant Parties warrant that their performance of the Consulting Services will not violate (i) any applicable law, rule, or regulation;
(ii) any contracts with any third-parties, or (iii) any third-party rights in any patent, trademark, service mark, trade name, copyright,
trade secret, or other property. The Consultant Parties further warrant that they are the lawful owners or licensees of any software
programs or other materials used by the Consultant Parties in the performance of the Consulting Services and that the Consultant Parties
have all rights necessary to convey to the Company the unencumbered ownership of any Developments, work product, and/or other deliverables.

 

(b) The
Consultant Parties hereby represent and warrant that they are not currently engaged, nor will they engage during the term of this Agreement
hereunder, in or on any other project or matter (including, without limitation, the provision of similar services to parties other than
the Company) that might reasonably be construed to be in conflict with the Consulting Services.

 

11. Termination.

 

(a) Either
the Consultant or the Company may terminate the Consulting Services at any time by giving the other Party at least ten (10) days’
prior written notice.

 

(b) If
the Consulting Services are terminated by the Company prior to February 28, 2023, subject to Consultant’s continued compliance
with any restrictive covenants by which the Consultant may be bound, the Consulting Options shall automatically vest and become exercisable
as of the termination date, which shall satisfy all of the Company’s obligations to the Consultant. If the Consulting Services
are terminated by the Consultant prior to February 28, 2023, (x) the Consultant shall retain any Consulting Options that are vested as
of the termination date and (y) the Consultant shall automatically forfeit the Consulting Options that are unvested as of the termination
date for no consideration, which shall satisfy all of the Company’s obligations to the Consultant. The retained vested Consulting
Options shall remain subject to the terms and conditions of the Equity Plan and applicable award agreement.

 

    	5

     

    

 

12. Miscellaneous.

 

(a) Entire
Agreement. Except as provided in Section 5(e), this Agreement constitutes the entire agreement of the Parties and replaces and supersedes
any prior agreements, understandings, or arrangements between any of the Company Parties, on the one hand, and any of the Consultant
Parties, on the other hand with respect to the subject matters contained herein.

 

(b) Amendment;
Waiver. This Agreement may not be amended, altered, waived, or superseded except by a written an instrument signed by the Consultant
and another of the Company. A waiver of any breach of this Agreement, or the failure to enforce any term or provision of this Agreement,
shall not in any way affect, limit, or waive a Party’s rights to fully enforce the same or any other term or provision of this
Agreement in the future.

 

(c) Successors
and Assigns. The Consultant will not assign, transfer, or subcontract this Agreement or any of the Consultant’s obligations
hereunder without the prior written consent of the Company. This Agreement shall inure to the benefit of the successors and assigns of
the Company, and the Company may, without Consultant’s prior consent, assign its rights and obligations under this Agreement or
any part hereof to one or more of the Company Parties or as otherwise permitted by law, or assign this Agreement in its entirety to a
successor to all or substantially all of its business or assets to which this Agreement relates.

 

(d) Governing
Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Tennessee, regardless of the
laws that might otherwise govern under applicable principles of conflicts of law.

 

(e) Notices.
All notices, demands and other communications hereunder shall be in writing and shall be given both by email and by overnight delivery
(either FedEx or UPS) as follows: (i) in the case of the Consultant, to the last address and/or email address on file with the Company
and (ii) in the case of the Company, to its executive offices, attention to the General Counsel or, in each case, to such other address,
and with such other copies, as either Party may hereafter specify in writing in accordance with this Section 12(e) for the purpose of
receiving notice. Each such notice or other communication shall be effective at the time so indicated by the confirmation of delivery
provided by UPS or FedEx.

 

(f) Severability.
If any provision or clause of this Agreement is found to be invalid or unenforceable under any applicable law, this Agreement shall be
considered severable and divisible, and an arbitrator or reviewing court shall have the authority to “blue pencil” or otherwise
modify this Agreement so as to make it fully valid and enforceable while enforcing the original intent of the parties, as reflected herein,
to the maximum extent possible.

 

(g) Construction.
This Agreement shall be interpreted strictly in accordance with its terms, to the maximum extent permissible under governing law, and
shall not be construed against or in favor of any Party, regardless of which Party drafted this Agreement or any provision hereof.

 

(i) Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original and all of which together shall
constitute one and the same instrument. True and accurate copies of this Agreement shall have the same force and effect as original hereof.

 

(j) Third
Party Beneficiaries. Each and all of the Company Parties are intended third-party beneficiaries of this Agreement and shall have
standing to enforce this Agreement in accordance with its terms.

 

(k) Survival.
Sections 3, 4(c), 5, 6, 7, 8, 9, 10, 11, and 12 of this Agreement (the “Surviving Provisions”) shall survive the termination
of the Consulting Services hereunder and shall remain in full force and effect following such termination.

 

[Signature
page follows]

 

    	6

     

    

 

The
Company and the Consultant have duly executed this Agreement:

 

	 	ONCOCYE CORPORATION
	 	 
	 	By:	/s/ Andy Arno
	 	Name:	 Andy Arno
	 	Title:	 Chairman of the Board of Directors
	 	Date:	12/02/2022

 

	 	RONALD A. ANDREWS
	 	 
	 	Signature:	/s/ Ronald Andrews
	 	   
	 	Date:	12/02/2022

 

    	7

     

    

 

APPENDIX
A

 

Consulting
Services

 

Consultant
shall devote an average of 10 hours per week to discharge the Consulting Services contemplated hereby, including the provision of services
to facilitate the transition of responsibility of the Chief Executive Officer role, as may be reasonably required by the person(s) identified
in Section 2 of the Consulting Agreement.

 

Appendix A to Consulting AgreementExhibit
10.3

 

EMPLOYMENT
AGREEMENT

 

EMPLOYMENT
AGREEMENT (“Agreement”) is entered into effective as of December 2, 2022 (the “Effective Date”),
by and between OncoCyte, Corporation (the “Company”), a California corporation located at 15 Cushing, Irvine, California
92618 and Joshua Riggs (“Executive”).

 

WITNESSETH:

 

WHEREAS,
the Company desires to continue to employ Executive on the terms and conditions set forth herein; and

 

WHEREAS,
Executive desires to be employed by the Company on such terms and conditions.

 

NOW,
THEREFORE, in consideration of the terms and conditions hereinafter set forth, the parties hereto agree as follows:

 

1.
Engagement; Position and Duties.

 

(a)
Position and Duties. During the Term (as defined below) until such time as a permanent Chief Executive Officer commences employment,
the Company agrees to employ Executive in the position of Interim Chief Executive Officer of the Company (“Interim CEO”).
In such position, Executive shall have such duties and responsibilities attendant to the position of Interim Chief Executive Officer
and shall render services consistent with such position, as applicable and appropriate and such services as the Board of Directors of
the Company (the “Board of Directors”) may from time to time direct or require. As Interim CEO, Executive shall report
to the Board of Directors. At such time that a permanent Chief Executive Officer commences employment with the Company (such date, the
“CEO Commencement Date”), (i) Executive shall serve as a senior executive of the Company with such duties and responsibilities
that are reasonably agreed between Executive and the Board of Directors and (ii) Executive will be deemed to have automatically resigned
as Interim CEO (and any positions or offices affiliated with such title, including as a director of the Board of Director, if applicable).
During the Term, Executive shall devote best efforts, skills and abilities, on a full-time basis, exclusively to the Company’s
business. Executive covenants and agrees to faithfully adhere to and fulfill such policies as are established from time to time by the
Board of Directors or the Company (“Policies”).

 

(b)
Place of Performance. Executive’s principal place of employment with the Company shall be at the Company’s headquarters
in Irvine, California, or as otherwise determined from time to time by the Board of Directors, provided that Executive shall perform
Executive’s duties and responsibilities hereunder with due care and in accordance with all Company policies (including any remote-working
policies as in effect from time to time), and provided further that Executive understands and agrees that Executive may be required to
travel from time to time for business purposes.

 

(c)
Performance of Services for Subsidiaries. In addition to the performance of services for Company, Executive shall, to the extent
so required by Company, also perform services for one or more members of a consolidated group of which Company is a part, provided that
such services are consistent with the kind of services Executive performs or may be required to perform for Company under this Agreement.
If Executive performs any services for any subsidiary that is wholly-owned or partially owned by OncoCyte (each a “Subsidiary”),
Executive shall not be entitled to receive any compensation or remuneration in addition to or in lieu of the compensation and remuneration
provided under this Agreement on account of such services for the Subsidiary. The Policies will govern Executive’s employment by
Company and any Subsidiaries for which Executive is asked to provide Services. In addition, Executive covenants and agrees that Executive
will faithfully adhere to and fulfill such additional policies as may be established from time to time by the board of directors of any
Subsidiary for which Executive performs services, including to the extent that such policies and procedures differ from or are in addition
to the Policies adopted by Company.

 

    	Page 1

     

    

 

(d)
No Conflicting Obligations. Executive represents and warrants to Company that Executive is under no obligations or commitments, whether
contractual or otherwise, that are inconsistent with Executive’s obligations under this Agreement or that would prohibit Executive,
contractually or otherwise, from performing Executive’s duties as under this Agreement and the Policies.

 

(e)
No Unauthorized Use of Third Party Intellectual Property. Executive represents and warrants to Company that Executive will not use
or disclose, in connection with Executive’s employment by Company or any Subsidiary, any patents, trade secrets, confidential information,
or other proprietary information or intellectual property as to which any other person has any right, title or interest, except to the
extent that Company or a Subsidiary holds a valid license or other written permission for such use from the owner(s) thereof. Executive
represents and warrants to Company that Executive has returned all property and confidential information belonging to any prior employer.

 

(f)
The “Term” shall mean the period commencing as of the Effective Date and continuing
until the earlier of (i) such time as Executive’s employment is terminated in accordance with Section 5 or (ii) the one-year anniversary
of the Effective Date. To the extent Executive’s employment with the Company continues beyond the end of the Term, Executive will
continue as an “at-will” employee, such that either party may terminate Executive’s employment at any time, for any
reason or no reason.

 

2.
Compensation

 

(a)
Salary. During the Term, Executive’s annual base salary shall be Three Hundred Thousand Dollars ($300,000) (pro-rated for partial
years), less applicable taxes and deductions (such annual base salary, “Base Salary”). Executive’s Base Salary
shall be paid in accordance the Company’s regular salary payment practices, as in effect from time to time.

 

(b)
Bonus. During the Term, Executive shall be eligible to receive an annual cash bonus (the “Annual Bonus”) with
a target bonus opportunity equal to 50% of base salary. Executive’s Annual Bonus, if any, for calendar year 2022, shall be subject
to the achievement of the parameters and objectives used to determine the amount of the Annual Bonus immediately prior to the Effective
Date, assessed and determined by the Board (or committee thereof). Executive’s Annual Bonus, if any, for calendar year 2023, shall
be based on and subject to the achievement of Company and/or individual performance objectives established (in consultation with Executive),
approved, assessed and determined by the Board (or a committee thereof).

 

Notwithstanding
the foregoing, Executive’s Annual Bonus, if any, earned, if at all, shall be determined as follows: (i) in respect of the 2022
calendar year: (A) the portion of Executive’s Annual Bonus, if any, that relates to Executive’s employment with the Company
from January 1, 2022, through the day immediately prior to the Effective Date, shall be calculated based on the target bonus opportunity
in effect immediately prior the Effective Date applicable to the base salary paid to Executive during such period and (B) the portion
of Executive’s Annual Bonus, if any, that relates to Executive’s employment with the Company from the Effective Date through
December 31, 2022, shall be calculated based on a target bonus opportunity equal to 50% applicable to the base salary paid to Executive
during such period, and (ii) in respect of the 2023 calendar year: (A) the portion of Executive’s Annual Bonus, if any, that relates
to Executive’s employment with the Company from January 1, 2023, through the one year anniversary of the Effective Date, shall
be calculated based on a target bonus opportunity equal to 50% applicable to the base salary paid to Executive during such period and
(B) the portion of Executive’s Annual Bonus, if any, that relates to Executive’s employment with the Company from the day
after the one year anniversary of the Effective Date through December 31, 2023, shall be calculated based on the target bonus opportunity,
determined by the Board (or committee thereof), which shall not be less than the target bonus opportunity in effect immediately prior
to the Effective Date, applicable to the base salary paid to Executive during such period.

 

The
Annual Bonus shall not be earned until paid and shall not be paid unless Executive remains an employee (and has not received notice of
termination of employment for Cause) of Company on the date of payment.

 

    	Page 2

     

    

 

(c)
Stock Options. The Company shall grant Executive a one-time award under the Company’s 2018 Equity Incentive Plan, as amended
from time to time (the “Plan”) of options to purchase 250,000 shares of Company “Common Stock,”
as defined in the Plan, effective three business days following the Effective Date (the “Equity Grant”). The exercise
price of the options in the Equity Grant shall be the fair market value of a share of Company Common Stock on the applicable effective
date of grant, determined in accordance with the Plan. Executive shall execute a stock option agreement provided by the Company consistent
with the terms of the option grant and the Plan. The options in the Equity Grant shall vest and thereby become exercisable upon the one-year
anniversary of the Effective Date, upon Executive’s completion of one year of continuous service as an employee of Company or of
a Subsidiary from the Effective Date subject to Executive’s continued compliance with any restrictive covenants by which Executive
may be bound. Continuous service shall have the meaning ascribed in the Plan. Except to the extent that provisions of the Plan relating
to termination of continuous service as an employee apply to the termination of options, to the extent not exercised, the options shall
expire ten years from the effective date of grant. The options shall be incentive stock options to the extent permitted by Section 422
of the Internal Revenue Code of 1986, as amended (the “Code”).

 

(d)
Expense Reimbursements. During the Term, the Company or a Subsidiary shall reimburse Executive for reasonable and necessary travel
and other business expenses incurred by Executive in the performance of Executive’s duties under this Agreement, subject to necessary
documentation and in accordance with the Company’s Policies and procedures in effect from time to time.

 

(e)
Benefit Plans. During the Term, Executive may be eligible (to the extent Executive qualifies) to participate in certain retirement,
pension, life, health, accident and disability insurance, equity incentive plan or other similar employee benefit plans, which may be
adopted by Company for its executive officers or other employees. Company and the Subsidiaries have the right, at any time and without
any amendment of this Agreement, and without prior notice to or consent from Executive, to adopt, amend, change, or terminate any such
benefit plans that may now be in effect or that may be adopted in the future, in each case without any further financial obligation to
Executive; provided that such unilateral change does apply to Executive in a manner different than other Company executives or employees
of a comparable executive level, except for changes required by applicable federal, state, or local law, or implemented in response to
any change of federal, state or local law or regulation. Any benefits to which Executive may be entitled under any benefit plan shall
be governed by the terms and conditions of the applicable benefit plan, and any related plan documents, as in effect from time to time.
If Executive receives any grant of stock options or stock or stock related equity awards (“Awards”) under any stock
option plan, stock purchase plan, or other equity incentive plan of Company (an “Equity Plan”), the terms and conditions
of the Award, and Executive’s rights with respect to the Award, shall be governed by (i) the terms of the Equity Plan, as the same
may be amended from time to time, and (ii) the terms and conditions of any stock option agreement, stock purchase agreement, or other
agreement that Executive may sign or be required to sign with respect to any Award.

 

(f)
Vacation; Sick Leave. During the Term, Executive shall be entitled to paid time off and sick leave in accordance with the Policies
of the Company. Executive’s vacation shall be taken at such time as is consistent with the needs and Policies of Company and its
Subsidiaries. All vacation days and sick leave days shall accrue annually based upon days of service. Executive’s right to leave
from work due to illness is subject to the Policies and the provisions of this Agreement governing termination due to disability, sickness
or illness. The Policies governing the disposition of unused vacation days and sick leave days remaining at the end of Company’s
fiscal year shall govern whether unused vacation days or sick leave days will be paid, lost, or carried over into subsequent fiscal years.

 

(g)
Indemnification. The Company shall enter into the Company’s standard form indemnification agreement for officers and directors
with Executive.

 

3.
Inventions/Intellectual Property/Confidential Information. Executive acknowledges the execution and delivery to Company of an Employee
Confidential Information and Inventions Assignment Agreement” (the “Confidentiality and IP Agreement”), attached
hereto as Exhibit A.

 

    	Page 3

     

    

 

4.
Additional Restrictive Covenants.

 

(a)
Cooperation. Executive agrees that during Executive’s employment with the Company and thereafter (regardless of whether
Executive resigns or is terminated, or the reason for such resignation or termination), Executive shall, without any additional consideration,
provide reasonable and timely cooperation in connection with (a) any actual or threatened litigation, inquiry, review, investigation,
process, or other matter, action, or proceeding (whether conducted by or before any arbitrator, court, regulatory, or governmental entity,
or otherwise, or by or on behalf of the Company, any Subsidiary, or any of their respective affiliates), that relates to events occurring
during Executive’s employment with the Company or about which the Company otherwise believes Executive may have relevant information;
(b) the transitioning of Executive’s role and responsibilities to other personnel; and (c) the provision of information in response
to the Company’s requests and inquiries in connection with Executive’s separation and/or relating to topics about which the
Company otherwise believes Executive may have relevant information. Executive’s cooperation shall include being available to (i)
meet with and provide information to the Company and each of the Company Entities (as defined below) and each and all of their respective
shareholders, interest holders, unit holders, advisors, managers, officers, directors, partners, principals, members, employees, fiduciaries,
representatives, and agents (each a “Company Party”) and their counsel or other agents in connection with fact-finding,
investigatory, discovery, and/or pre-litigation or other proceeding issues, and (ii) provide truthful testimony (including via affidavit,
deposition, at trial, or otherwise) in connection with any such matter, all without the requirement of being subpoenaed. The Company
shall try to schedule Executive’s cooperation pursuant to this Section so as not to unduly interfere with Executive’s other
personal or professional pursuits

 

(b)
Non-Disparagement; Non-Publicity. Except as provided in Section 1.6 of the Confidentiality and IP Agreement, Executive agrees
that, both during and after Executive’s employment, Executive will not, whether in private or in public, directly or indirectly,
make, publish, encourage, ratify, or authorize, or aid, assist, or direct any other person or entity in making or publishing, whether
in written, oral, digital, or any other form: (a) any statements, postings, or other communications that are defamatory, malicious, or
slanderous about, or that are misrepresentative of any of the Company, any Subsidiary, or any of their respective agents, affiliates,
customers, directors, employees, executives, investors, officers, members, or representatives, or (b) any statements, postings, or other
communications that in any way defame, damage, or disparage the Company and its current former or future parents, subsidiaries, affiliates,
or related entities (the “Company Entities”) or their respective investors, products, employees, partners, or services.
Further, Executive agrees not to do any of the following except as within the performance of Executive’s lawful and authorized
duties within the scope of Executive’s employment with the Company or pursuant to the explicit written approval of the Company:
(i) communicate with any member of the media concerning any Company Party, (ii) make any statement, posting, or other communication in,
on, to, or through any media (whether print, television, radio, the internet, social media, or with or through any reporter, blogger,
“app” (such as TikTok, Instagram, Snapchat, or the like), or otherwise (collectively “Media”)) that purports
to be on behalf of any Company Party, or which a third party may perceive (A) has been authorized, approved, or endorsed by a Company
Party or (B) reflects the views of any Company Party, or otherwise includes any Confidential Information, (iii) conduct any Company business
activity on any Media, (iv) provide any Company Party’s promotional material to any person or entity, or (v) direct, aid, encourage,
or assist any other person or entity to do any of the foregoing; provided that nothing in this Section 3(c) shall be construed in a manner
that would violate any law. Nothing in this Agreement prevents Employee from discussing or disclosing information about unlawful acts
in the workplace, such as harassment or discrimination or any other conduct that Employee has reason to believe is unlawful. Further,
nothing in this Agreement prevents Executive from discussing or disclosing information about unlawful acts in the workplace, such as
harassment or discrimination or any other conduct that Employee has reason to believe is unlawful.

 

5.
Termination of Employment. During the Term:

 

(a)
Resignation by Executive. Executive may resign Executive’s employment at any time, for
any reason, or for no reason upon at least thirty (30) days prior written notice to the Company; provided, however that the notice requirements
upon a resignation for Good Reason shall be the notice required pursuant to the definition of Good Reason (as defined below), provided
further that the Company may, at any time during such 30-day period, relieve Executive from all or any of Executive’s duties for
all or part of the remainder of such 30-day period (including a requirement that Executive must stay away from all or any of the Company’s
premises and/or will not be provided with any work and/or will have no business contact with all or any of the Company’s agents,
employees, customers, clients, distributors and suppliers) and provided further that the Company may, in its sole discretion, waive all
or part of such notice period, in which case Executive’s employment shall terminate on such date as directed by the Company.

 

    	Page 4

     

    

 

(b)
Termination by the Company without Cause. The Company may terminate Executive’s employment
without Cause (as defined below) at any time.

 

(c)
Termination by the Company for Cause. The Company may terminate Executive’s employment
with Cause at any time upon written notice to Executive.

 

(d)
Termination Upon Death or Disability. Executive’s employment shall terminate automatically
upon Executive’s death. If Executive sustains a Disability (as defined below) while Executive is employed by the Company, the Company
may terminate Executive’s employment by giving Executive thirty (30) days written notice of the Company’s intent to terminate
Executive’s employment. Notwithstanding the foregoing, nothing in this Section 5(d) shall
be construed to waive Executive’s rights, if any, under applicable law.

 

6.
Payments Due Upon Termination of Employment. Except as otherwise provided in this Agreement, upon termination
of Executive’s employment, Company and the Subsidiaries shall have no further obligation to Executive, by way of compensation or
otherwise.

 

(a)
Upon termination of Executive’s employment with Company at any time and for any reason, in the
event of the termination of Executive’s employment by Company for Cause, or termination of Executive’s employment as a result
of death, Disability, Executive’s resignation for Good Reason or without Good Reason, Executive will be entitled to receive only
the severance benefits set forth below and those provided in the Severance Agreement, if applicable, pursuant to the terms and conditions
thereof, and Executive will not be entitled to any other compensation, award, or damages with respect to Executive’s employment
or termination of employment.

 

(i)
Termination for Cause, Death, Disability, or Resignation without Good Reason. In the event of the termination of Executive’s
employment by Company for Cause, or termination of Executive’s employment as a result of death, Disability, or resignation, Executive
will be entitled to receive payment for all accrued but unpaid salary actually earned prior to or as of the date of termination of Executive’s
employment, and vacation or paid time off accrued as of the date of termination of Executive’s employment. Executive will not be
entitled to any cash severance benefits or additional vesting of any stock options or other equity or cash awards except as provided
in Section 5(a)(ii) or the Severance Agreement, in the event of a termination of Executive’s employment by Company without Cause
or if Executive resigns for Good Reason, subject to the terms and conditions of Section 5(a)(ii) and the Severance Agreement, as applicable.

 

(ii)
Termination Without Cause or Resignation for Good Reason. In the event of a termination of Executive’s employment by Company
without Cause (excluding due to Disability) or Executive resigns for Good Reason, subject to Executive’s continued compliance with
any restrictive covenants by which Executive may be bound, including but not limited to those contained in Section 3 hereof and those
set forth in the Confidentiality and IP Agreement, Executive will be entitled to (A) the benefits set forth in Section (a)(i) and (B)
if the date of termination occurs: (x) during the Term, a pro-rated portion of the Annual Bonus, if any, for the year of termination,
based on actual performance (determined by multiplying the amount of such Annual Bonus which would be due for the full fiscal year by
a fraction, the numerator of which is the number of days during the fiscal year of termination that Executive is employed by the Company
and the denominator of which is 365) or (y) after the Term but prior to the payment of the Annual Bonus, if any, in respect of the 2023
fiscal year, a pro-rated portion of the Annual Bonus, if any, in respect of the 2023 fiscal year, based on actual performance (determined
by multiplying the amount of such Annual Bonus which would be due for the full fiscal year by a fraction, the numerator of which is the
number of days during the fiscal year of termination that Executive is employed by the Company and the denominator of which is 365),
in each case, paid on the later of (x) the first regularly scheduled payroll date following the 60th day following Executive’s
termination of employment and (y) in the calendar year following the calendar year to which the Annual Bonus relates on the date such
Annual Bonus would have been paid if Executive’s employment had not terminated.

 

    	Page 5

     

    

 

(b)
Release. The Company’s obligation to make such payments under Section (a)(ii) and provide any other such benefits contemplated
herein shall be contingent upon Executive’s execution of a release in a form and containing such substance as reasonably acceptable
to the Company (the “Release”), which Release must be signed and any applicable revocation period with respect thereto
must have expired by the 30th day following Executive’s termination of employment (or such other time period as required by applicable
law). The Release will not waive any of Executive’s rights, or obligations of the Company or its successor in interest and the
Subsidiaries, regarding: (1) any right to indemnification and/or contribution, advancement or payment of related expenses Executive may
have pursuant to the Company’s Bylaws, Articles of Incorporation, under any written indemnification or other agreement between
the parties, and/or under applicable law; (2) any rights that Executive may have to insurance coverage under any directors and officers
liability insurance, other insurance policies of the Company, COBRA or any similar state law; (3) any claims for worker’s compensation,
state disability or unemployment insurance benefits, or any other claims that cannot be released as a matter of applicable law; (4) rights
to any vested benefits under any stock, compensation or other employee benefit plan of the Company; (5) any rights Executive may have
as an existing shareholder of the Company; and (6) any claims arising after the effective date of the Release. Nothing in the Release
or any other agreement between Executive and the Company will prohibit or prevent Executive from providing truthful testimony or otherwise
responding accurately and fully to any question, inquiry or request for information or documents when required by legal process, subpoena,
notice, court order or law (including, without limitation, in any criminal, civil, or regulatory proceeding or investigation), or as
necessary in any action for enforcement or claimed breach of this Agreement or any other legal dispute with the Company.

 

(c)
Section 280G of the Code.

 

(i)
Notwithstanding anything in this Agreement to the contrary, if any payment, distribution, or other benefit provided by the Company to
or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise
(collectively, the “Payments”), (x) constitute a “parachute payment” within the meaning of Section 280G
of the Code, and (y) but for this Section 5(c) would be subject to the excise tax imposed by Section 4999 of the Code or any similar
or successor provision thereto (the “Excise Tax”), then the Payments shall be either: (A) delivered in full pursuant
to the terms of this Agreement, or (B) delivered to such lesser extent as would result in no portion of the payment being subject to
the Excise Tax, as determined in accordance with Section 5(b).

 

(ii)
The determination of whether Section 5(c)(i)(A) or Section 5(c)(i)(B) shall be given effect shall be made by the Company on the basis
of which of such clauses results in the receipt by Executive of the greater Net After-Tax Receipt (as defined herein) of the aggregate
Payments. The term “Net After-Tax Receipt” shall mean the present value (as determined in accordance with Section
280G of the Code) of the payments net of all applicable federal, state and local income, employment, and other applicable taxes and the
Excise Tax.

 

(iii)
If Section 5(c)(i)(B) is given effect, the reduction shall be accomplished in accordance with Section 409A of the Code and the following:
first by reducing, on a pro rata basis, cash Payments that are exempt from Section 409A of the Code; second by reducing, on a pro rata
basis, other cash Payments; and third by forfeiting any equity-based awards that vest and become payable, starting with the most recent
equity-based awards that vest, to the extent necessary to accomplish such reduction.

 

    	Page 6

     

    

 

(iv)
Unless the Company and Executive otherwise agree in writing, any determination required under this Section 5(c) shall be made by the
Company’s independent accountants or compensation consultants (the “Third Party”), and all such determinations
shall be conclusive, final and binding on the parties hereto. The Company and Executive shall furnish to the Third Party such information
and documents as the Third Party may reasonably request in order to make a determination under this Section 5(c). The Third Party shall
provide detailed supporting calculations both to the Company and Executive. The Company shall bear all fees and costs of the Third Party
with respect to all determinations under or contemplated by this Section 5(c).

 

(v)
If, at the time of a transaction giving rise to Payments that could constitute “parachute payments” within the meaning of
Section 280G of the Code, the stock of the Company is not readily tradable on an established securities market and the Company determines
that the exemption described in Section 280G(b)(5) of the Code would apply to the Payments if the requisite shareholder approval is obtained
in accordance with the terms and conditions of Section 280G of the Code, the Company shall use commercially reasonable efforts to seek
the requisite shareholder approval of the Payments such that no Payments would constitute “excess parachute payments.”

 

(d)
Definitions. For purposes of this Section, the following definitions shall apply:

 

(i)
“Cause” shall have the meaning ascribed to such term in the Severance Agreement.

 

(ii)
“Disability” shall mean Executive’s inability to perform the essential functions of Executive’s job responsibilities,
despite any reasonable accommodation required by applicable law, for a period of one hundred eighty (180) days in the aggregate in any
twelve (12) month period.

 

(iii)
“Good Reason” shall have the meaning ascribed to such term in the Severance Agreement.

 

(iv)
“Severance Agreement” shall mean that certain amended and restated change in control and severance agreement plan
entered into by and between the Company and Executive, effective as of December 2, 2022.

 

7.
Turnover of Property and Documents on Termination. Executive agrees that on or before termination of Executive’s employment,
or at any other time at the Company’s or Board of Director’s request, Executive will return to Company, and all Subsidiaries,
all equipment and other property belonging to Company and the Subsidiaries, and all originals and copies of confidential information
(in any and all media and formats, and including any document or other item containing Confidential Information as defined in Exhibit
A) in Executive’s possession or control, and all of the following (in any and all media and formats, and whether or not constituting
or containing confidential information) in Executive’s possession or control: (a) lists and sources of customers; (b) proposals
or drafts of proposals for any research grant, research or development project or program, marketing plan, licensing arrangement, or
other arrangement with any third party; (c) reports, notations of the Executive, laboratory notes, specifications, and drawings pertaining
to the research, development, products, patents, and technology of Company and any Subsidiaries; (d) any and all intellectual property
developed by Executive during the course of employment; and (e) the manual and memoranda related to the Policies. To the extent there
is a conflict between this Section 6 and the Confidentiality and IP Agreement executed by the Executive, the Confidentiality and IP Agreement
provisions control.

 

8.
Resignation as a Director on Termination of Employment. Upon termination of Executive’s employment for any reason by either
party, Executive hereby agrees that Executive shall automatically be treated as having resigned from any offices or positions related
to the Company (including as a member of the Board of Directors, if applicable) or any of its affiliates, and shall timely execute any
documents required to effectuate the same.

 

    	Page 7

     

    

 

9.
Arbitration. It is the intention of Executive and Company that the Federal Arbitration Act and the California Arbitration Act shall
apply with respect to the arbitration of disputes, claims, and controversies pursuant to, arising under, or in connection with this Agreement
(including its Exhibit A Confidentiality and IP Agreement). Except for injunctive proceedings against unauthorized disclosure
of confidential information or other actual or threatened breach of this Agreement or its Exhibit A Confidentially and IP Agreement
that may cause irreparable and continuing injury to the Company or its subsidiaries or affiliates for which there is no adequate remedy
at law (and upon the issuance or denial of an injunction the underlying merits of any dispute will be resolved in accordance with the
remainder of this Section), any and all claims or controversies between Company or any Subsidiary and Executive, including but not limited
to (a) those involving the construction or application of any of the terms, provisions, or conditions of this Agreement or the Policies;
(b) all contract or tort claims of any kind; and (c) any claim based on any federal, state, or local law, statute, regulation, or ordinance,
shall be settled by arbitration in accordance with the then current Employment Dispute Resolution Rules of the American Arbitration Association
(“AAA”) or the Employment Arbitration Rules & Procedures of the Judicial Arbitration and Mediation Service (“JAMS”),
as selected by Company or a Subsidiary. Judgment on the award rendered by the arbitrator(s) may be entered by any court having jurisdiction
over Company and Executive. The location of the arbitration shall be San Francisco, California. Unless Company or a Subsidiary and Executive
mutually agree otherwise, the arbitrator shall be a retired judge selected from a panel provided by the AAA or the JAMS. Company, or
a Subsidiary, if the Subsidiary is a party to the arbitration proceeding, shall pay the arbitrator’s fees and costs. Executive
shall pay for Executive’s own costs and attorneys’ fees, if any. Company and any Subsidiary that is a party to an arbitration
proceeding shall pay for its own costs and attorneys’ fees, if any. However, if any party prevails on a statutory claim which affords
the prevailing party attorneys’ fees, the arbitrator may award reasonable attorneys’ fees and costs to the prevailing party.
Notwithstanding the foregoing, nothing in this Section shall be construed in a manner that would violate any law.

 

EXECUTIVE
UNDERSTANDS AND AGREES THAT THIS AGREEMENT TO ARBITRATE CONSTITUTES A WAIVER OF EXECUTIVE’S RIGHT TO A TRIAL BY JURY OF ANY MATTERS
COVERED BY THIS AGREEMENT TO ARBITRATE.

 

10.
Severability. In the event that any of the provisions of this Agreement or the Policies shall be held to be invalid or unenforceable
in whole or in part, those provisions to the extent enforceable and all other provisions shall nevertheless continue to be valid and
enforceable as though the invalid or unenforceable parts had not been included in this Agreement or the Policies. In the event that any
provision relating to a time period of restriction shall be declared by an arbitrator or court of competent jurisdiction to exceed the
maximum time period such arbitrator or court deems reasonable and enforceable, then the time period of restriction deemed reasonable
and enforceable by the arbitrator or court shall become and shall thereafter be the maximum time period.

 

11.
Agreement Read and Understood. Executive acknowledges that Executive has carefully read the terms of this Agreement, that Executive
has had an opportunity to consult with an attorney or other representative of Executive’s own choosing regarding this Agreement,
that Executive understands the terms of this Agreement and that Executive is entering this Agreement of Executive’s own free will.

 

12.
Complete Agreement, Modification. This Agreement, the Confidentiality and IP Agreement, and the Severance Agreement are the complete
agreement between Executive and Company on the subjects contained in this Agreement. This Agreement supersedes and replaces all previous
correspondence, promises, representations, and agreements, if any, either written or oral with respect to Executive’s employment
by Company or any Subsidiary and any matter covered by this Agreement. No provision of this Agreement may be modified, amended, or waived
except by a written document signed both by Company and Executive.

 

13.
Governing Law. This Agreement shall be construed and enforced according to the laws of the State of California.

 

14.
Assignability. This Agreement, and the rights and obligations of Executive and Company under this Agreement, may not be assigned
by Executive. Company may assign any of its rights and obligations under this Agreement to any successor or surviving corporation, limited
liability company, or other entity resulting from a merger, consolidation, sale of assets, sale of stock, sale of membership interests,
or other reorganization, upon condition that the assignee shall assume, either expressly or by operation of law, all of Company’s
obligations under this Agreement.

 

    	Page 8

     

    

 

15.
Taxes.

 

(a)
Generally. The Company or any Subsidiary may withhold from any payments made under this Agreement all
applicable taxes, including, but not limited to, income, employment and social insurance taxes as shall be required by law. Executive
acknowledges and represents that the Company has not provided any tax advice to Executive in connection with this Agreement and that
Executive has been advised by the Company to seek tax advice from Executive’s own tax advisors regarding this Agreement and payments
that may be made to Executive pursuant to this Agreement.

 

(b)
Section 409A. Notwithstanding anything herein to the contrary, this Agreement is intended to be interpreted
and applied so that the payments and benefits set forth herein shall either be exempt from the requirements of Section 409A of the Code,
and the rules and regulations promulgated thereunder (“Section 409A”), or shall comply with the requirements of such
provision and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be exempt from or in compliance with
Section 409A. To the extent the Company determines that any provision of this Agreement would cause Executive to incur any additional
tax or interest under Section 409A, the Company shall be entitled to reform such provision to attempt to comply with or be exempt from
Section 409A through good faith modifications. To the extent that any provision hereof is modified in order to comply with Section 409A,
such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and
economic benefit to Executive and the Company without violating the provisions of Section 409A. Notwithstanding anything in this Agreement
or elsewhere to the contrary, a termination of employment shall not be deemed to have occurred for purposes of any provision of this
Agreement providing for the payment of any amounts or benefits that constitute “non-qualified deferred compensation” within
the meaning of Section 409A upon or following a termination of Executive’s employment unless such termination is also a “separation
from service” within the meaning of Section 409A. For purposes of any such provision of this Agreement, references to a “termination,”
“termination of employment” or like terms shall mean a “separation from service” and the date of such separation
from service shall be the date of termination for purposes of any such payment or benefits. Each payment under this Agreement or otherwise
in a series of payments shall be treated as a separate payment for purposes of Section 409A. In no event may Executive, directly or indirectly,
designate the calendar year of any payment to be made under this Agreement or otherwise which constitutes a “deferral of compensation”
within the meaning of Section 409A. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in
accordance with the requirements of Section 409A. To the extent that any reimbursements pursuant to this Agreement or otherwise are taxable
to Executive, any reimbursement payment due to Executive shall be paid to Executive on or before the last day of Executive’s taxable
year following the taxable year in which the related expense was incurred; provided, that, Executive has provided the Company written
documentation of such expenses in a timely fashion and such expenses otherwise satisfy the Company’ or one of its subsidiaries’
expense reimbursement policies. Reimbursements pursuant to this Agreement or otherwise are not subject to liquidation or exchange for
another benefit and the amount of such reimbursements that Executive receives in one taxable year shall not affect the amount of such
reimbursements that Executive receives in any other taxable year. Notwithstanding any provision in this Agreement to the contrary, if
on the date of Executive’s termination from employment with the Company Executive is deemed to be a “specified employee”
within the meaning of Section 409A using the identification methodology selected by the Company from time to time, or if none, the default
methodology under Section 409A, any payments or benefits due upon a termination of Executive’s employment under any arrangement
that constitutes a “deferral of compensation” within the meaning of Section 409A shall be delayed and paid or provided (or
commence, in the case of installments) on the first payroll date on or following the earlier of (i) the date which is six (6) months
and one (1) day after Executive’s termination of employment for any reason other than death, and (ii) the date of Executive’s
death, and any remaining payments and benefits shall be paid or provided in accordance with the normal payment dates specified for such
payment or benefit. Each payment under this Agreement will be treated as a separate payment for purposes of Section 409A and the right
to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. Notwithstanding
any of the foregoing to the contrary, the Company and its affiliates and its and their respective officers, directors, employees, or
agents make no guarantee that the terms of this Agreement as written comply with, or are exempt from, the provisions of Section 409A,
and none of the foregoing shall have any liability for the failure of the terms of this Agreement as written to comply with, or be exempt
from, the provisions of Section 409A.

 

    	Page 9

     

    

 

16.
Survival. The covenants and agreements contained in Sections 3, 4, 7, and 9-15 of this Agreement, as well as the Confidentiality
and IP Agreement, shall survive termination of this Agreement and Executive’s employment.

 

17.
Notices. Any notices or other communication required or permitted to be given under this Agreement shall be in writing and shall
be mailed by certified mail, return receipt requested, or sent by next business day air courier service, personally delivered to the
party to whom it is to be given, or transmitted via electronic mail. Notices will be deemed to have been given hereunder and received
when delivered personally, when received if transmitted via electronic mail, five (5) days after deposit in the U.S. mail and one (1)
day business after deposit for next business day. Notices shall be addressed as follows (or to such other address as the party shall
have furnished in writing in accordance with the provisions of this Section 17):

 

If
to the Company:

 

OncoCyte
Corporation

15
Cushing

Irvine,
California 92618

Attention:
General Counsel

 

If
to Executive, to Executive’s physical and/or email address most recently on file with the Company.

 

[Signatures
to the Employment Agreement Are Found on the Following Page]

 

    	Page 10

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

 

	EXECUTIVE:	 
	 	 
	 	/s/
Joshua Riggs	 
	 	Joshua
    Riggs	 
	 	 	 
	COMPANY:	 
	 	 	 
	ONCOCYTE
    CORPORATION	 
	 	 	 
	By:	/s/
Andy Arno	 
	 	 	 
	Title:	Chairman
    of the Board	 

 

Signature
Page to Employment Agreement (Joshua Riggs)

 

    	 

     

    

 

Exhibit
A

 

EMPLOYEE
CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT

 

In
consideration of my continued employment by ONCOCYTE CORPORATION its subsidiaries, parents, affiliates, successors and assigns
(together “Company”) pursuant to the Employment Agreement effective as of December 2, 2022 (the “Employment
Agreement”) and the compensation paid to me now and during my employment with Company, I, Joshua Riggs, hereby enter into
this Employee Confidential Information and Invention Assignment Agreement (the “Agreement”) and agree as follows:

 

1.
Confidential Information Protections.

 

1.1
Recognition of Company’s Rights; Nondisclosure. I understand and acknowledge that my employment by Company creates a relationship
of confidence and trust with respect to Company’s Confidential Information (as defined below) and that Company has a protectable
interest therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or
publish any of Company’s Confidential Information, except as such disclosure, use or publication may be required in connection
with my work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company’s written
approval before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and/or incorporates
any Confidential Information. I hereby assign to Company any rights I may have or acquire in such Confidential Information and recognize
that all Confidential Information shall be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions
to prevent the inadvertent accidental disclosure of Confidential Information.

 

1.2
Confidential Information. The term “Confidential Information” shall mean any and all confidential knowledge,
data or information of Company. By way of illustration but not limitation, “Confidential Information” includes
(a) trade secrets, inventions, algorithms, mask works, ideas, processes, formulas, software in source or object code, data, programs,
other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology
and all Intellectual Property Rights (as defined below) therein (collectively, “Inventions”), and genetic and
protein biomarkers of any and all kinds used in or related to Company diagnostic tests, products, or research, even if not patented or
patentable; (b) information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished
financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures,
methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational
plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting
Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers of
Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered
by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought
to be provided to customers and potential customers of Company and other non-public information relating to customers and potential customers;
(d) information regarding any of Company’s business partners and their services, including names, representatives, proposals, bids,
contracts and their contents and parties, the type and quantity of products and services received by Company, and other non-public information
relating to business partners; (e) information regarding personnel, employee lists, compensation, and employee skills; and (f) any other
non-public information which a competitor of Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing,
it is understood that, at all such times, I am free to use information which was known to me prior to my employment with Company or which
is generally known in the trade or industry through no breach of this Agreement or other act or omission by me.

 

1.3
Third Party Information. I understand, in addition, that Company has received and in the future will receive from third parties their
confidential and/or proprietary knowledge, data or information (“Third Party Information”) subject to a duty
on Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During the
term of my employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company
personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for
Company, Third Party Information or unless expressly authorized by an officer of Company in writing.

 

    	Employee Confidential Information and Inventions Assignment Agreement 
 Joshua Riggs Page 1

     

    

 

1.4
Term of Nondisclosure Restrictions. I understand that Confidential Information and Third Party Information is never to be used or
disclosed by me, as provided in this Section 1, except in connection with my lawful and authorized duties as an employee of the Company
during my employment or as otherwise provided in Section 1.6 below..

 

1.5
No Improper Use of Information of Prior Employers and Others. During my employment by Company, I will not improperly use or disclose
confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality,
and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other
person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.

 

1.6
.. Notwithstanding anything herein to the contrary, in accordance with the Defend Trade Secrets Act, 18 U.S.C. § 1833(b), and other
applicable law, nothing in this Section 1, the Employment Agreement to which it is an Exhibit, or any other agreement or Company policy
shall prevent Executive from, or expose Executive to criminal or civil liability under federal or state trade secrets law for (i) directly
or indirectly, sharing any Company Party’s (as defined in the Employment Agreement) trade secrets or other Confidential Information
(except information protected by any Company Party’s attorney-client or work product privilege) with law enforcement, an attorney,
or any federal, state, or local government agencies, regulators, or officials (including the Equal Employment Opportunity Commission,
the Securities and Exchange Commission, the California Labor & Workforce Development Agency, or any other analogous state or local
agencies), for the purpose of investigating or reporting a suspected violation of law (including but not limited to any whistleblower
retaliation claim), whether in response to a subpoena or otherwise, without notice to the Company; (ii) disclosing any Company Party’s
trade secrets in a filing in connection with a legal claim including but not limited to any whistleblower retaliation claim), provided
that the filing is made under seal; (iii) discussing or disclosing information related to Executive’s general job duties or responsibilities;
and/or (iv) in any way participating in any action seeking to rectify or address sexual harassment or other illegal conduct, or from
making such good faith based allegations relating to sexual harassment, harassment, discrimination, or any other conduct prohibited by
law, in accordance with the terms of this Agreement.

 

2.
Assignments of Inventions.

 

2.1
Definitions. As used in this Agreement, the term “Intellectual Property Rights” means all trade secrets,
Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or
country; the term “Copyright” means the exclusive legal right to reproduce, perform, display, distribute and
make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or
country; and the term “Moral Rights” means all paternity, integrity, disclosure, withdrawal, special and any
other similar rights recognized by the laws of any jurisdiction or country.

 

2.2
Excluded Inventions and Other Inventions. Attached hereto as Annex A is a list describing all existing Inventions, if any,
(a) that are owned by me or in which I have an interest and were made or acquired by me prior to my date of first employment by Company,
(b) that may relate to Company’s business or actual or demonstrably anticipated research or development, and (c) that are not to
be assigned to Company (“Excluded Inventions”). If no such list is attached, I represent and agree that it
is because I have no Excluded Inventions. For purposes of this Agreement, “Other Inventions” means Inventions
in which I have or may have an interest, as of the commencement of my employment or thereafter, other than Company Inventions (as defined
below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of
my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any
Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any
rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise
in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not
I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide
license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly
perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer
for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any
third parties have rights in any such Other Inventions, I hereby represent and warrant that such third party or parties have validly
and irrevocably granted to me the right to grant the license stated above.

 

    	Employee Confidential Information and Inventions Assignment Agreement 
 Joshua Riggs Page 2

     

    

 

2.3
Assignment of Company Inventions. Inventions assigned to Company or to a third party as directed by Company pursuant to Section 2.6
are referred to in this Agreement as “Company Inventions.” Subject to Section 2.4 and except for Excluded Inventions
set forth in Annex A and Other Inventions, I hereby assign to Company all my right, title, and interest in and to any and all
Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either
alone or with others, during the period of my employment by Company. To the extent required by applicable Copyright laws, I agree to
assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and
to such Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes
an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed
by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights,
and all claims and causes of action of any kind against Company or related to Company’s customers, with respect to such rights.
I further acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions
(and any Intellectual Property Rights with respect thereto).

 

2.4
Unassigned or Nonassignable Inventions. I recognize that this Agreement will not be deemed to require assignment of any Invention
that is covered under California Labor Code section 2870(a) (the “Specific Inventions Law”) except for those
Inventions that are covered by a contract between Company and the United States or any of its agencies that require full title to such
patent or Invention to be in the United States.

 

2.5
Obligation to Keep Company Informed. During the period of my employment, I will promptly and fully disclose to Company in writing
all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others. At the time of each such disclosure,
I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions
Law; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence
and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to
Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.

 

2.6
Government or Third Party. I agree that, as directed by Company, I will assign to a third party, including without limitation the
United States, all my right, title, and interest in and to any particular Company Invention.

 

2.7
Ownership of Work Product. I agree that Company will exclusively own all work product that is made by me (solely or jointly with
others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to Company all right, title and interest
worldwide in and to such work product. I acknowledge that all original works of authorship which are made by me (solely or jointly with
others) within the scope of my employment and which are protectable by Copyright are “works made for hire,” pursuant to United
States Copyright Act (17 U.S.C., Section 101). I understand and agree that I have no right to publish on, submit for publishing, or use
for any publication any work product protected by this Section, except as necessary to perform services for Company.

 

2.8
Enforcement of Intellectual Property Rights and Assistance. I will assist Company in every proper way to obtain, and from time to
time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries.
To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company
may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property
Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to
Company or its designee, including the United States or any third party designated by Company. My obligation to assist Company with respect
to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of
my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company’s
request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document
needed in connection with the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint Company and its
duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and on
my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding
paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any
nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement
to Company.

 

    	Employee Confidential Information and Inventions Assignment Agreement 
 Joshua Riggs Page 3

     

    

 

2.9
Incorporation of Software Code. I agree that I will not incorporate into any Company software or otherwise deliver to Company any
software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms,
requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or
licensed by Company except in strict compliance with Company’s policies regarding the use of such software.

 

3.
Records. I agree to keep and maintain adequate and current records (in the form of
notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all
Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property
of Company at all times.

 

4.
Duty of Loyalty During Employment. I agree that during the period of my employment
by Company, I will not, without Company’s express written consent, directly or indirectly engage in any employment or business
activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment by Company.

 

5.
No Solicitation of Employees, Consultants or Contractors. I agree that during the period
of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary
termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or
in any other capacity, either directly or through others, except on behalf of Company, solicit, canvass, approach, encourage, entice
or induce any employee or contractor of the Company (or individual who was an employee or contractor of the Company at any point during
the twelve (12) months preceding the date of such solicitation or other similar act), with whom I had direct contact with or had access
to Confidential Information about by virtue of the my employment with Company, to terminate or lessen his, her or its employment or engagement
with the Company..

 

6.
Reasonableness of Restrictions.

 

6.1
I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not prevent me from earning a
living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company’s
legitimate business interests. I represent and agree that I am entering into this Agreement freely and with knowledge of its contents
with the intent to be bound by the Agreement and the restrictions contained in it.

 

6.2
To the extent permitted by applicable law, in the event that an arbitrator or court finds this Agreement, or any of its restrictions,
to be ambiguous, unenforceable, or invalid, I and Company agree that the arbitrator or court will read the Agreement as a whole and interpret
the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.

 

6.3
To the extent permitted by applicable law, if the arbitrator or court declines to enforce this Agreement in the manner provided in
subsection 6.2, Company and I agree that this Agreement will be automatically modified to provide Company with the maximum protection
of its business interests allowed by law and I agree to be bound by this Agreement as modified.

 

7.
No Conflicting Agreement or Obligation. I represent that my performance of all the
terms of this Agreement and as an employee of Company does not and will not breach any agreement to keep in confidence information acquired
by me in confidence or in trust prior to my employment by Company. I have not entered into, and I agree I will not enter into, any agreement
either written or oral in conflict with this Agreement.

 

    	Employee Confidential Information and Inventions Assignment Agreement 
 Joshua Riggs Page 4

     

    

 

8.
Return of Company Property. When I leave the employ of Company, or at any other time
as requested by the Company or the Board of Directors, I will deliver to Company any and all drawings, notes, memoranda, specifications,
devices, formulas and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions,
Third Party Information or Confidential Information of Company. I agree that I will not copy, delete, or alter any information contained
upon my Company computer or Company equipment before I return it to Company. In addition, if I have used any personal computer, server,
or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information,
I agree to provide Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge
such Confidential Information from those systems; and I agree to provide Company access to my system as reasonably requested to verify
that the necessary copying and/or deletion is completed. I further agree that any property situated on Company’s premises and owned
by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company’s
personnel at any time with or without notice. Prior to leaving, I will cooperate with Company in attending an exit interview and completing
and signing Company’s termination statement if required to do so by Company.

 

9.
Legal and Equitable Remedies.

 

9.1
. I agree that my breach or threatened breach of any of the restrictions set forth this Agreement will result in irreparable and
continuing damage to the Company for which there is no adequate remedy at law. Thus, in addition to the Company’s right to arbitrate
disputes relating to this Agreement (as set forth in the Employment Agreement), the Company shall be entitled to obtain emergency equitable
relief, including a temporary restraining order and/or preliminary injunction, in aid of arbitration, from any state or federal court
of competent jurisdiction, without first posting a bond, to restrain any such breach or threatened breach. Such relief shall be in addition
to any and all other remedies, including damages, available to the Company and its affiliates against me for such breaches or threatened
breaches. Upon the issuance (or denial) of an injunction, the underlying merits of any dispute will be resolved in accordance with the
arbitration provisions contained in the Employment Agreement.

 

9.2
In the event Company enforces this Agreement through an arbitration or court order, I agree that the restrictions of Section 5 will
be tolled during the period of such breach and remain in effect for a period of 12 months from the effective date of the Order enforcing
the Agreement.

 

10.
Notices. Any notices required or permitted under this Agreement will be given to Company
in accordance with the notice provisions contained in the Employment Agreement.

 

11.
Publication of This Agreement to Subsequent Employer or Business Associates of Employee.

 

11.1
If I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity
while the restrictions described in Section 5 of this Agreement are in effect I agree to inform my potential employer, partner, co-owner
and/or others involved in managing the business with which I have an opportunity to be associated of my obligations under this Agreement
and also agree to provide such person or persons with a copy of this Agreement.

 

11.2
I agree to inform the Company of all employment and business ventures which I enter into while the restrictions described in Section
5 of this Agreement are in effect and I also authorize Company to provide copies of this Agreement to my employer, partner, co-owner
and/or others involved in managing the business with which I am employed or associated and to make such persons aware of my obligations
under this Agreement.

 

12.
General Provisions.

 

12.1
Governing Law; Dispute Resolution. This Agreement will be governed by and construed according to the laws of the State of California
as such laws are applied to agreements entered into and to be performed entirely within California between residents of California. Any
disputes arising form or relating to this Agreement shall be resolved in accordance with the arbitration clause contained in the Employment
Agreement.

 

12.2
Severability. In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason,
be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other
provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been
contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to
be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as
to be enforceable to the extent compatible with the applicable law as it will then appear.

 

    	Employee Confidential Information and Inventions Assignment Agreement 
 Joshua Riggs Page 5

     

    

 

12.3
Successors and Assigns. This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations,
Subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.

 

12.4
Survival. This Agreement shall survive the termination of my employment, regardless of the reason, and the assignment of this Agreement
by Company to any successor in interest or other assignee.

 

12.5
Employment At-Will. I agree and understand that nothing in this Agreement will change my at-will employment status or confer any
right with respect to continuation of employment by Company for any specific period of time.

 

12.6
Waiver. No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by
Company of any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice
to enforce strict adherence to all terms of this Agreement.

 

12.7
Export. I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any
products utilizing such data, in violation of the United States export laws or regulations.

 

12.8
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which
shall be taken together and deemed to be one instrument. This Agreement may also be executed and delivered by facsimile signature, PDF
or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com).

 

12.9
Advice of Counsel. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT
LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT WILL NOT BE
CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.

 

    	Employee Confidential Information and Inventions Assignment Agreement 
 Joshua Riggs Page 6

     

    

 

This
Agreement shall be effective as of December 2, 2022.

 

	 	EMPLOYEE:
	 	 	 
	 	/s/ Josh Riggs
	 	 	(Signature)
	 	 	 
	 	 
	 	 	Joshua
    Riggs
	 	 	 
	 	COMPANY:
	 	 	 
	 	ACCEPTED
    AND AGREED
	 	 	 
	 	ONCOCYTE
    CORPORATION
	 	 	 
	 	By:	/s/
    Andy Arno
	 	 	Andy
    Arno
	 	 	Chairman
    of the Board of Directors

 

	 	Address:	15
    Cushing 

    Irvine, California 92618

 

    	Employee Confidential Information and Inventions Assignment Agreement 
 Joshua Riggs Page 7

     

    

 

Annex
A

To The

EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT

 

EXCLUDED
INVENTIONS

 

	TO:	OncoCyte
    Corporation
	FROM:	Joshua
    Riggs
	DATE:	 

 

1.
Excluded Inventions Disclosure. Except as listed in Section 2 below, the following is a complete list of all Excluded Inventions:

 

	 	☐	No Excluded Inventions.
	 	 	 
	 	☐	See
    below:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	☐	Additional sheets attached.

 

2.
Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with respect to the Excluded Inventions
generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies):

 

	Excluded
    Invention	 	Party(ies)	 	Relationship
	1.	 	 	 	 
	2.	 	 	 	 
	3.	 	 	 	 

 

		☐	Additional
                                            sheets attached.

 

3.
Limited Exclusion Notification.

 

This
is to notify you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and Company does
not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company’s
equipment, supplies, facilities or trade secret information, except for those Inventions that either:

 

a.
Relate at the time of conception or reduction to practice to Company’s business, or actual or demonstrably anticipated research
or development; or

 

b.
Result from any work performed by you for Company.

 

To
the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding
paragraph, the provision is against the public policy of this state and is unenforceable.

 

This
limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its
agencies requiring full title to such patent or Invention to be in the United States.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]